iA Global Asset Management Inc. Boosts Stock Position in Insulet Corporation $PODD

iA Global Asset Management Inc. boosted its position in Insulet Corporation (NASDAQ:PODD) by 45.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,710 shares of the medical instruments supplier’s stock after purchasing an additional 3,334 shares during the quarter. iA Global Asset Management Inc.’s holdings in Insulet were worth $2,247,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PODD. Larson Financial Group LLC raised its stake in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet during the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new stake in Insulet in the fourth quarter valued at approximately $28,000. DV Equities LLC acquired a new stake in Insulet in the fourth quarter valued at approximately $28,000. Finally, MV Capital Management Inc. purchased a new position in Insulet in the fourth quarter worth $29,000.

Insulet Trading Up 2.9%

Shares of Insulet stock opened at $164.48 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12-month low of $138.79 and a 12-month high of $354.88. The firm has a market capitalization of $11.39 billion, a price-to-earnings ratio of 38.25, a PEG ratio of 1.11 and a beta of 1.11. The firm’s 50 day simple moving average is $155.81 and its two-hundred day simple moving average is $216.27.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts predict that Insulet Corporation will post 6.46 EPS for the current year.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Raymond James Financial set a $216.00 price target on Insulet in a research report on Monday, June 8th. TD Cowen lowered their price objective on Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a research report on Monday, June 1st. Stifel Nicolaus dropped their target price on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. UBS Group set a $219.00 target price on Insulet in a research report on Thursday, June 11th. Finally, William Blair began coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.67.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: TipRanks highlighted multiple ongoing Insulet clinical programs, including Optimal-B, Omnipod 6 vs. Omnipod 5, and the EVOLVE trial for Omnipod M. These studies may support the long-term growth story by expanding evidence for Omnipod systems and the company’s type 2 diabetes opportunity. Article Title
• Positive Sentiment: A Seeking Alpha article argued that Insulet is a high-quality growth company trading at a reasonable PEG ratio, reinforcing the view that the stock may have upside potential if growth remains strong. Article Title
• Neutral Sentiment: Insulet said it will report second-quarter 2026 financial results on August 5. The upcoming earnings date keeps attention on execution and guidance, but it is not a direct catalyst by itself. Article Title
• Negative Sentiment: Pomerantz LLP announced a class-action lawsuit against Insulet and certain officers, alleging violations of federal securities laws for investors who bought shares during the stated class period. Litigation risk and possible legal costs can weigh on sentiment. Article Title
• Negative Sentiment: Additional law-firm notices from Howard G. Smith and Robbins LLP reinforced the same securities-fraud class-action overhang, adding to investor caution around PODD. Article Title

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.